Michael Egholm

Pall Corp. designs, manufactures, and markets filtration and separation equipment. Its products are used to remove solid, liquid, and gaseous contaminants from a variety of liquids and gases. The firm has Life Sciences and Industrial segments. The Life Sciences segment focuses on developing, manufacturing, and selling products to customers in the medical, biopharmaceuticals, and food and beverage markets. The Industrial segment focuses on developing, manufacturing and selling products to customers in the process technologies, aerospace, and microelectronics markets. The company was founded by David B. Pall on July 31, 1946 and is headquartered in Port Washington, NY.

IsoPlexis Corp. engages in the development of curative medicines and personalized therapeutics. Its single cell proteomics platform, which includes instruments, chip consumables and software, provides an end-to-end solution to reveal a more complete view of protein function at an individual cellular level. The company was founded by Sean Mackay, Rong Fan, and Kara K. Brower in March 2013 and is headquartered in Branford, CT.

Molecular Staging, Inc. (MSI) developed products for the detection & measurement of proteins and nucleic acids. The company's amplification technologies included products & services that identify individual and multiplexed sets of biomarkers & a method of generating DNA from a few cells. MSI enabled transformational products and services across multiple health care markets. The company was founded in 1998 and was located in New Haven, CT.

454 Life Sciences Corp. engages in the provision of medical testing services to determine the nucleotide sequence of whole genomes. The company was founded by Jonathan M. Rothberg in 2000 and is headquartered in Branford, CT.

Roche Applied Science operates as a biotechnology firm focused on researches in molecular diagnostics. The company is headquartered in Indiana.

Abbratech, Inc. is a biotechnology company that focuses on precision antibodies. Abbratech is based in Branford, CT. The company offers services such as antigen and project design, recombinant antibody development, antibody optimization, and antibody production. Abbratech uses the best available in vivo and in vitro methods for antibody discovery and applies knowledge gained from the past 15 years of human genome sequencing and antibody engineering to produce high affinity and highly specific recombinant antibodies. The company was founded in 2020 by Michael P. Weiner, who has been the CEO since then.